Key points are not available for this paper at this time.
The Swiss drug services firm Lonza has agreed to acquire a biologic facility in Vacaville, California, owned by Roche's Genentech unit for 1. 2 billion in cash. The facility, deemed one of the largest in the world for biologic manufacturing, has a bioreactor capacity of about 330, 000 L. Lonza will invest an additional 560 million to upgrade the site. In the future, Lonza will supply Roche products currently manufactured at the site.
Aayushi Pratap (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: